Immucell (ICCC) Interest Expenses (2010 - 2026)
Immucell's (ICCC) quarterly Interest Expenses came in at $153003.0 in Q4 2025, up 22.57% YoY from $124830.0 in Q4 2024, and down 97.83% on a QoQ basis from $7.0 million in Q3 2025.
Immucell (ICCC) Interest Expenses (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Interest Expenses data on file, last reported at $153003.0 in Q4 2025.
- Quarterly Interest Expenses rose 22.57% year-over-year to $153003.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $568151.0 (up 98.49% YoY) and the FY2025 annual result came in at $4.9 million, up 7.24% from the prior year.
- Interest Expenses retreated to $153003.0 in Q4 2025, from $7.0 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $7.6 million in Q2 2025 to a low of -$1.9 million in Q3 2024.
- A 5-year average of $741875.6 and a median of $126184.0 in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses surged 1493.94% — and 2023, when it plunged 816.94%.
- Tracing ICCC's Interest Expenses over 5 years: stood at $74358.0 in 2021, then gained by 25.95% to $93652.0 in 2022, then slumped by 179.64% to -$74582.0 in 2023, then surged by 267.37% to $124830.0 in 2024, then gained by 22.57% to $153003.0 in 2025.
- The last three Interest Expenses figures came in at $153003.0 (Q4 2025), $7.0 million (Q3 2025), and $7.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | 95,667.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95,667.00 |
| Jun 30, 2026 | 95,667.00 |
| Dec 31, 2025 | 153,003.00 |
| Dec 31, 2025 | 153,003.00 |
| Sep 30, 2025 | 7.05 Mn |
| Sep 30, 2025 | 7.05 Mn |
| Jun 30, 2025 | 7.64 Mn |
| Jun 30, 2025 | 7.64 Mn |
| Mar 31, 2025 | 144,315.00 |
| Mar 31, 2025 | 144,315.00 |
| Dec 31, 2024 | 124,830.00 |
| Dec 31, 2024 | 124,830.00 |
| Sep 30, 2024 | -1.89 Mn |
| Sep 30, 2024 | -1.89 Mn |
| Jun 30, 2024 | -1.16 Mn |
| Jun 30, 2024 | -1.16 Mn |
| Mar 31, 2024 | 146,003.00 |
| Mar 31, 2024 | 146,003.00 |
| Dec 31, 2023 | -74,582.00 |
| Dec 31, 2023 | -74,582.00 |